Foresee Pharmaceuticals Co., Ltd.

TPEX:6576 Stock Report

Market Cap: NT$12.3b

Foresee Pharmaceuticals Valuation

Is 6576 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 6576 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 6576's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 6576's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6576?

Key metric: As 6576 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6576. This is calculated by dividing 6576's market cap by their current revenue.
What is 6576's PS Ratio?
PS Ratio30.6x
SalesNT$401.12m
Market CapNT$12.29b

Price to Sales Ratio vs Peers

How does 6576's PS Ratio compare to its peers?

The above table shows the PS ratio for 6576 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
6620 Handa Pharmaceuticals
8.9xn/aNT$15.6b
3705 YungShin Global Holding
1.8xn/aNT$14.3b
1720 Standard Chemical & Pharmaceutical
1.6xn/aNT$11.2b
4114 Synmosa Biopharma
2.4xn/aNT$15.1b
6576 Foresee Pharmaceuticals
30.6xn/aNT$12.3b

Price-To-Sales vs Peers: 6576 is expensive based on its Price-To-Sales Ratio (30.6x) compared to the peer average (3.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 6576's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?

17 CompaniesPrice / SalesEstimated GrowthMarket Cap
1795 Lotus Pharmaceutical
2x28.29%US$1.51b
3705 YungShin Global Holding
1.8xn/aUS$448.91m
1720 Standard Chemical & Pharmaceutical
1.6xn/aUS$351.63m
4746 Formosa Laboratories
1.3xn/aUS$191.72m
6576 30.6xIndustry Avg. 3.9xNo. of Companies17PS0816243240+
17 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6576 is expensive based on its Price-To-Sales Ratio (30.6x) compared to the TW Pharmaceuticals industry average (3.9x).

Price to Sales Ratio vs Fair Ratio

What is 6576's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6576 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6576's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

NT$153
Fair Value
49.0% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/27 14:53
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Foresee Pharmaceuticals Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullKGI Securities Co. Ltd.
Hsuan ChenKGI Securities Co. Ltd.
Xin Ying JiangYuanta Research